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Abstract
Ewing sarcoma is the second most common bone cancer in children and adolescents, with
poor prognosis and outcome in ~70% of initial diagnoses and 10–15% of relapses. Hydro-
phobic triterpene acids and hydrophilic lectins and viscotoxins from European mistletoe
(Viscum album L.) demonstrate anticancer properties, but have not yet been investigated
for Ewing sarcoma. Commercial Viscum album L. extracts are aqueous, excluding the insol-
uble triterpenes. We recreated a total mistletoe effect by combining an aqueous extract (vis-
cum) and a triterpene extract (TT) solubilized with cyclodextrins. Ewing sarcoma cells were
treated with viscum, TT and viscumTT in vitro, ex vivo and in vivo. In vitro and ex vivo treat-
ment of Ewing sarcoma cells with viscum inhibited proliferation and induced apoptosis in a
dose-dependent fashion, while viscumTT combination treatment generated a synergistic
effect. Apoptosis occurred via intrinsic and extrinsic apoptotic pathways, evidenced by acti-
vation of both CASP8 and CASP9. We show that viscumTT treatment shifts the balance of
apoptotic regulatory proteins towards apoptosis, mainly via CLSPN, MCL1, BIRC5 and
XIAP downregulation. ViscumTT also demonstrated strong antitumor activity in a cell line-
and patient-derived mouse model, and may be considered an adjuvant therapy option for
pediatric patients with Ewing sarcoma.
Introduction
Ewing sarcoma, while the second most common bone sarcoma in children and adolescents
(peaking in the second decade), is rare and occurs in ~2.6 and ~2.8 per million children in the
United States and Germany, respectively [1,2]. It originates from either mesenchymal stem or
neuronal crest cells [3,4]. Pathogenesis results from a balanced translocation of the EWS gene
producing fusion proteins coding for chimeric transcription factors promoting cell growth.
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EWS-FLI1 is the most frequent fusion protein [5,6]. Therapeutic advances in the last few
years support five-year survival in 70% of Ewing sarcoma patients. Standard therapy currently
combines surgery, chemotherapy and radiotherapy, but relapse tumors are often drug resis-
tant [7]. Patient outcome for relapsed Ewing sarcoma is poor, with cure in only 10–15% of
patients [8]. Stage, anatomical localization, and tumor size influence prognosis [7]. Expres-
sion of the inhibitor of apoptosis protein (IAP) family member, BIRC5 (formerly survivin), is
also a poor prognostic factor for Ewing sarcoma [9,10]. BIRC5 has been suggested as an
attractive target for new anticancer agents, since it is expressed in many cancers but not in dif-
ferentiated normal tissues [11]. XIAP, another IAP family member, is also overexpressed in
multiple cancers and is associated with drug resistance, making it another promising thera-
peutic target [12,13]. Combining targeted agents in current protocols might improve survival
by reducing resistance development.
European mistletoe, Viscum album L., has been popular in anthroposophic medicine for
decades. A broad range of biologically active substances have been identified in Viscum album
L., and include viscotoxins, flavonoids, triterpene acids and mistletoe lectins [14–18]. Commer-
cial aqueous Viscum album L. extracts contain the hydrophilic mistletoe lectins (ML) I-III,
which are the best studied compounds from mistletoe [19,20]. MLI-III have been demonstrated
to stimulate the immune system and induce apoptotic cell death in cell lines derived from head
and neck squamous cell carcinomas [21] and rat glioma [22] as well as in a single alternatively
treated patient with a stage IIIC colon carcinoma [23].
The hydrophobic triterpene acids, oleanolic, betulinic and ursolic acid, represent another
potent group of mistletoe-derived substances, although their low solubilities exclude them
from commercially available aqueous extracts [24]. Solubilizing mistletoe triterpene acids
(mainly oleanolic and betulinic acids) with cyclodextrins in a buffered aqueous solution pro-
duces the triterpene extract, TT. Triterpene acids, including oleanolic acid, its derivatives and
betulinic acid, inhibit cell growth and induce apoptosis in cell lines derived from breast [25],
ovarian [26] and nonsmall cell lung cancers [27] as well as neuroectodermal tumors in vitro
and ex vivo [28]. Combination of oleanolic and ursolic acid has been reported to act synergisti-
cally against melanoma cells in vitro and in vivo [29].
We and others have already demonstrated the therapeutic effect of recombining hydrophilic
and hydrophobic mistletoe constituents in the viscumTT extract for acute lymphoblastic and
myeloid leukemia in vitro and in vivo [30,31] and murine melanoma in vivo [32]. Here, we ana-
lyzed for the first time the cytotoxic effect of viscumTT and its single extracts in Ewing sarcoma
in vitro, ex vivo and in vivo.
Materials and Methods
Viscum album L. extracts
Viscum and TT extracts were prepared from Viscum album L. harvested from apple trees
(malus) as previously described [30,31,33] by the Birken AG (Niefern-Oeschelbronn, Ger-
many), who kindly provided lyophilized viscum and TT extracts. Intact ML-I (with A+B
chain) was quantified by ELISA in viscum extract [34]. Oleanolic acid and betulinic acid quan-
tification was performed by GC-FID [33]. Lyophilized viscum extract was reconstituted in
phosphate-buffered saline (Gibco1 Life Technologies, Darmstadt, Germany) to a final concen-
tration of 2μg/mL intact ML-I and<1μg/mL viscotoxins. Lyophilized TT extract (containing
cyclodextrins) was reconstituted in phosphate-buffered saline to a final concentration of
4000μg/mL oleanolic and 350μg/mL betulinic acid.
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Cell culture
Human Ewing sarcoma cell lines were obtained from the German Collection of Microorgan-
isms and Cell Cultures (DSMZ, Braunschweig, Germany). TC-71 was maintained in Iscove's
Modified Dulbecco's Medium with L-glutamine (Gibco1 Life Technologies, Darmstadt, Ger-
many). MHH-ES-1 was maintained RPMI 1640 base medium with L-glutamine (Gibco Life-
technologies). Base media were supplemented with 10% heat-inactivated fetal calf serum
(Biochrom, Berlin, Germany), 100U/mL penicillin and 100μg/mL streptomycin (Biochrom).
For assays, 2x105 TC-71 cells and 4x105 MHH-ES-1 cells were seeded onto 6-well plates (half
the cell number onto 12-well microtiter plates), cultured 24h to allow cell attachment and
treated 24h with Viscum album L. extracts added to culture media.
Ex vivo cultured Ewing sarcoma primary cells
A tumor sample was obtained as treatment 'residue' from a 15-year-old girl with Ewing sar-
coma during routine surgical resection, and was not explicitly collected for this research. Diag-
nosis was confirmed by histopathology. The sample was dissected into smaller pieces
immediately after surgical excision, then cultured as a primary explant in RPMI 1640 base
medium with L-glutamine supplemented with 20% heat-inactivated fetal calf serum and 1%
penicillin/streptomycin solution (Biochrom) to obtain dissociated monolayer culture out-
growth from the explant. Confluent ex vivo cell cultures were treated within 4 trypsinized pas-
sages. CD99 expression confirmed ex vivo cultures to be Ewing sarcoma using
immunocytochemistry and flow cytometry with FITC-labeled anti-CD99 antibody (#561986,
BD Biosciences, Franklin Lakes, NJ, USA) versus the isotype control antibody (#555573). FISH
confirmed the EWS-ETS translocation in the ex vivo culture. Cells were seeded into 12-well
microtiter plates at 1.3x105/well, cultured 24h to allow cell attachment and treated 24h with
Viscum album L. extracts added to culture media. Written informed consent was obtained
from the patient's parents and/or legal guardians in accordance with the Declaration of Hel-
sinki, approved by the local ethics committee of Charité—Universitätsmedizin Berlin.
Ewing sarcoma xenografts and experimental procedures
Eight-week-old female NOD/SCID IL2rγ null mice and 6-8-weeks-old female NMRI-nu/nu
mice were obtained from Taconic or in-house breeding, housed in a pathogen-free facility
under pathogen-free conditions and fed autoclaved standard diet (Sniff, Soest, Germany) with
acidified drinking water ad libitum.
A) TC-71 cells (1x106) were subcutaneously injected in saline into the left flank of 8 NOD/
SCID IL2rγ null mice per treatment or control group. Intratumoral treatment with viscum, TT,
viscumTT or cyclodextrins alone (control group) began on day 12 when tumors were palpable.
Intravenous treatment with viscumTT or cyclodextrins began on day 3 after tumor cell injec-
tion. Mice were treated with increasing extract concentrations due to better tolerability: 40/50/
60mg/kg oleanolic acid (TT), 0.75/1.25/1.75μg/kg mistletoe lectin (viscum) or a combination
thereof (viscumTT). Doses were administered every 2–3 days (Mon/Wed/Fri/Mon/Fri) in
increasing concentrations and each concentration was given twice within 2–3 days due to bet-
ter tolerability of the mistletoe extracts. The standard-of-care group received doxorubicin with
4 mg/kg once, intravenously on day 12.
B) Patient-derived Ewing sarcoma fragments were subcutaneously transplanted into the left
flank of 5 mice per treatment or control group. Intratumoral and intravenous treatment with
viscumTT, cyclodextrins alone or doxorubicin (positive control group) began on day 48 when
tumors were palpable. Mice were treated with increasing extract concentrations of 40/60/
80mg/kg oleanolic acid and 0.75/1.25/1.75μg/kg mistletoe lectin in combination (viscumTT,
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low dose) or 50/70/90mg/kg oleanolic acid and 1.25/1.75/2.25μg/kg mistletoe lectin in combi-
nation (viscumTT, high dose). Doses were administered every 2–3 days (Wed/Fri/Mon/Wed/
Fri/Mon) in increasing concentrations and each concentration was given twice within 2–3
days. One positive control group received doxorubicin, 4 mg/kg, intravenously on day 48 and
day 55.
Body weight and tumor volume was measured twice weekly, and mice were daily monitored
for health and symptoms of toxicity. Animals were sacrificed by cervical dislocation at the end
of the experiment or if mice were moribund (tumor volume>1.2cm3 or>10% body weight
lost). Animal experiments were performed in accordance with German legislation on the care
and use of laboratory animals and in accordance with the United Kingdom Coordinating Com-
mittee on Cancer Research Guidelines for the Welfare of animals in Experimental Neoplasia to
minimize suffering. Approval for the study was obtained from the Regional Office for Health
and Social Affairs (LaGeSo, approval G-0030/15).
Determining cell proliferation and early cytotoxicity
Cells were counted using a CASY1 Cell Counter (Schaerfe System GmbH, Reutlingen, Ger-
many). Cell proliferation was estimated from total numbers of cells in cultures started from
defined cell numbers compared to control cultures. Early cytotoxicity was assessed after 2h of
incubation with extracts by photometrically (490nm) monitoring lactate dehydrogenase
(LDH) release into culture medium using the Cytotoxicity Detection Kit (Roche Diagnostics
GmbH, Mannheim, Germany) according to manufacturer´s instructions.
Assessing apoptotic cell death
Cells were stained with APC-conjugated annexin V (BD Biosciences) and 1 mg/mL propidium
iodide (Sigma-Aldrich, München, Germany) according to manufacturer’s instructions to assess
apoptosis. The mitochondrial membrane potential (ΔCm) was measured by JC-1 staining
(AAT Bioquest, Sunnyvale, CA, USA) according to manufacturer’s instructions. CASP3,
CASP8 and CASP9 activity were measured using the Green Caspase Staining Kit (Promokine,
Heidelberg, Germany) with the nontoxic, irreversibly caspase-binding cell-permeable FIT-
C-LEHD-FMK, FITC-IETD-FMK or FITC-DEVD-FMK, according to manufacturer’s direc-
tions. Cells stained using any of these protocols were analyzed by flow cytometry (FACS
Calibur, BD Biosciences), and results were evaluated with FlowJo Software (TreeStar, Ashland,
OR, USA).
Caspase inhibitor assay
TC-71 cells were incubated with 40μMZ-VAD-FMK (R&D systems, Minneapolis, MN, USA),
a pan-caspase inhibitor before treatment with viscum, TT or viscumTT extracts at ~IC50 con-
centrations. DMSO was added to extracts as solvent control. Apoptotic induction was deter-
mined by flow cytometry after annexin V/propidium iodide staining.
Proteome profiler human apoptosis array and western blotting
TC-71 cells were washed twice with phosphate-buffered saline, lysed in Lysis Buffer 17 (R&D
systems) containing complete Protease Inhibitor Cocktail (Roche Diagnostics GmbH) and pro-
tein concentration determined by Bradford assay (Bio-Rad, München, Germany). Lysate
(300μg protein) was incubated with the Proteome Profiler Human Apoptosis Array (R&D sys-
tems) according to manufacturer´s instructions. Chemoluminescence was visualized by densi-
tometry on a Molecular Imager ChemiDoc (Bio-Rad) to detect relative expression of
European Mistletoe in Ewing Sarcoma Treatment
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apoptosis-related proteins. Expression was validated using western blotting. TC-71 and
MHH-ES-1 cell lysates (30μg protein/lane) were separated on SDS-PAGE, transferred to nitro-
cellulose membranes (Bio-Rad system) and blocked with 5% nonfat milk in 50mM TBS with
0.05% Tween-20 (TBST) for 1h at room temperature. Blots were incubated overnight at 4°C in
TBST containing 5% bovine serum albumin and primary antibody, washed 3X in TBST and
incubated 1h with HRP-conjugated secondary antibodies (ant-rabbit or anti-mouse, Bio-Rad),
then visualized by ECL (Thermo Fisher Scientific, Bonn, Germany) on a Molecular Imager
ChemiDoc (Bio-Rad). Primary antibodies used were directed against CASP3 (#9662, Cell Sig-
naling Technology, Danvers, MN, USA), PARP1 (#9542, Cell Signaling Technology), CLSPN
(#2800, Cell Signaling Technology), BIRC5 (#2803, Cell Signaling Technology), TP53 (sc-
73566, Santa Cruz Biotechnology, Santa Cruz, CA, USA), PMAIP1 (sc-56169, Santa Cruz Bio-
technology) and MCL1 (sc-819, Santa Cruz Biotechnology), XIAP (#610716, BD Biosciences)
and ß-actin (#A3854, Sigma-Aldrich).
Statistics
In vitro experiments (except the Proteome Profiler Human Apoptosis Array) were performed
in three independent experiments, for which means ±standard error are plotted in bar graphs.
AWebb´s fractional product (Fp)>1 determined that the effect of viscumTT on apoptotic
induction in vitro and ex vivo was synergistic, as described [30]. One-way ANOVA and Fisher
´s LSD post-hoc tests were applied to determine differences between mouse xenograft treat-
ment groups. All results with p 0.05 were considered significant.
Results
ViscumTT inhibits proliferation and induces apoptosis in vitro
We first assessed the cytotoxic potential of aqueous and triterpene components separately or in
combination on Ewing cell lines in vitro to examine which extracts contained effectors from
Viscum album L. and detect potential synergies. TC-71 and MHH-ES-1 cell proliferation was
measured after incubation with increasing concentrations of viscum, TT or viscumTT. Vis-
cumTT and viscum inhibited proliferation in a concentration-dependent manner in both cell
lines (Fig 1 and S1 Table). TT had no effect on MHH-ES-1 cells, but displayed a low inhibitory
effect in TC-71 cells (Fig 1 and S1 Table). To exclude the possibility that extracts caused early
cytotoxicity via necrotic cell death, LDH release from cells into culture medium was measured
after a 2h treatment pulse. Neither cell line released significant amounts of LDH in response to
treatment with any extract (Fig 1 and S1 Table). We flow cytometrically assessed the fraction of
TC-71 and MHH-ES-1 cells undergoing apoptosis in response to 24h incubation with Viscum
album L. extracts after annexin V/propidium iodide staining. ViscumTT and viscum induced
apoptosis in both cell lines in a dose-dependent manner, whereas TT only induced apoptosis in
TC-71 cells (Fig 2A and S1 Table). Importantly, the reconstituted viscumTT extract displayed
a synergistic effect on apoptosis in both cell lines (Fig 2A and S1 Table). Western blot analyses
detecting PARP1 and CASP3 cleavage confirmed cells died from apoptotic induction (Fig 2B).
Taken together, reconstituting Viscum album L. cytotoxic compounds in viscumTT had a syn-
ergistic and dose-dependent effect on proliferation and apoptosis in Ewing sarcoma cell lines.
ViscumTT induces apoptosis via mitochondrial depolarization and
activates caspases in vitro
To more closely assess the mechanism behind viscumTT cytotoxicity, we analyzed mitochon-
drial involvement and caspase activation during apoptotic induction in TC-71 and MHH-ES-1
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cells, since most chemotherapeutic drugs induce mitochondrial membrane permeabilization as
they induce apoptosis [35,36]. Cell cultures treated for 24h with viscum, TT or viscumTT
extracts were flow cytometrically assessed after JC-1 staining to detect mitochondrial mem-
brane potentials relative to untreated control cultures. Treatment with viscumTT or viscum
alone resulted in a dose-dependent loss of mitochondrial membrane potential in TC-71 and
MHH-ES-1 cells (Fig 2C and S1 Table). Similar to its effect on apoptosis, viscumTT synergisti-
cally affected mitochondrial membrane depolarization, peaking at an 80% suppression of
membrane potential in both Ewing sarcoma cell lines (Fig 2C and S1 Table). TT treatment
alone did not significantly affect mitochondrial membrane potential in either cell line (Fig 2C
and S1 Table). We also measured the activation of CASP8, CASP9 and CASP3 in TC-71 and
Fig 1. ViscumTT inhibits proliferation in Ewing sarcoma cell lines without early cytotoxicity. TC-71 and MHH-ES-1 cells were treated with
increasing concentrations of TT, viscum or viscumTT for 24h and proliferation was estimated from total cell numbers in cultures started from defined cell
numbers compared to control cultures (upper graphs). Cells were counted using a CASY1 Cell Counter. TC-71 and MHH-ES-1 cells were incubated with
increasing concentrations of viscum, TT or viscumTT for 2h, before assessing early cytotoxicity via LDH release into the culture medium (lower graphs).
All results are presented as the percentage of untreated control (Ctrl) cultures ± SD, and are the mean of 3 independent experiments. Mistletoe lectin (ML)
and oleanolic acid (OA) concentrations were used as a measure of viscum and TT active agent extract concentration, respectively.
doi:10.1371/journal.pone.0159749.g001
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Fig 2. ViscumTT combined extract synergistically induces apoptosis in Ewing sarcoma cell lines. A. TC-71 and MHH-ES-1 cells were incubated
for 24h with increasing concentrations of viscum, TT and viscumTT. Cultures were then stained with annexin V and propidium iodide and examined by
flow cytometry. The percentage of dead cells in each treatment group are shown (±SD) from 3 independent experiments. A synergistic effect of the
combined viscumTT extract above single extracts was calculated byWebb´s fractional product (*Fp > 1). B. PARP1 and CASP3 cleavage was assessed
in whole-cell extracts from cells treated as described above using western blotting. β-actin was used as loading control, and images shown are
representative for the results in 3 independent experiments. C. TC-71 and MHH-ES-1 cells treated as above for 24h and were assessed for mitochondrial
involvement in apoptosis using JC-1 staining and flow cytometry. Bars depict the percentage of cells with low mitochondrial membrane potential (ΔΨm, ±
SD, n = 3) in each treatment group averaged from 3 independent experiments (±SD, error bars). A synergistic effect of combined viscumTT extracts was
European Mistletoe in Ewing Sarcoma Treatment
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MHH-ES-1 cells following 24h treatment with viscum, TT or viscumTT. A similarly potent
concentration-dependent caspase activation, reaching 80% in TC-71 and 90% in MHH-ES-1
cells, was observed in Ewing sarcoma cell lines after viscumTT or viscum treatment (Fig 3A
and S1 Table). ViscumTT also synergistically increased caspase activation above the effects of
viscum or TT extracts alone (Fig 3A and S1 Table). TT treatment, however, increased caspase
activation by only ~15% in TC-71 cells and did not affect caspase activation in MHH-ES-1
cells (Fig 3A and S1 Table). These results suggest that in addition to the intrinsic pathway, the
extrinsic apoptosis pathway also plays a role in viscum- and viscumTT-induced apoptosis. We
also treated TC-71 cells for 24h with viscum, TT or viscumTT extracts in the presence or
absence of the Z-VAD-FMK pan-caspase inhibitor. Z-VAD-FMK efficiently decreased apopto-
tic induction by up to 70% in cells treated with viscumTT or viscum and 30% in cells treated
with TT (Fig 3B and S1 Table), validating the essential role of caspases in viscumTT- and vis-
cum-induced apoptosis. These results reveal that Viscum album L. extracts induce apoptosis
via the intrinsic (mitochondrial) and extrinsic apoptosis pathways, and that viscumTT syner-
gistically reduces mitochondrial membrane polarization and caspase activation in Ewing sar-
coma cells in vitro.
Viscum, TT and viscumTT alter apoptosis-related protein expression
To more closely examine how mistletoe-derived cytotoxic agents induce apoptosis in Ewing
sarcoma cells, we analyzed the expression of 35 proteins related to apoptosis using the R&D
Systems human proteome profiler apoptosis array. TC-71 cells were treated with ~IC50 con-
centrations of viscum, TT or viscumTT. The array detected a shift of many proteins associated
with apoptosis in protein extracts from the treatment groups. Viscum, TT and viscumTT
reduced expression of the IAP family members, BIRC2 (cIAP1), BIRC3 (cIAP2), XIAP and
BIRC5, and to a lesser extent, BCL2 protein and TP53, compared to untreated control cells (Fig
4A). BIRC5 downregulation was particularly prominent. Altogether, expression shifted the bal-
ance towards less anti-apoptotic protein expression. Interestingly, the expression of claspin
(CLSPN), a protein needed for efficient DNA replication, was strongly suppressed by viscum,
TT and viscumTT. TT also strongly upregulated expression of the heat shock 60kDa protein 1
(HSPD1). Since the array could only be performed on a single treatment experiment, we vali-
dated results in TC71 and MHH-ES-1 lysates from three independent experiments using west-
ern blotting. Western blots confirmed that viscum, TT and viscumTT downregulated BIRC5,
XIAP, TP53 and CLSPN in Ewing sarcoma cells in vitro (Fig 4B). Since the pro-apoptotic
BCL2 family member, PMAIP1 (NOXA), was shown to play a role in apoptosis induced by
betulinic acid and doxorubicin polychemotherapy [37], we also analyzed PMAIP1 expression
in extracts from cells treated with viscum, TT or viscumTT. TT treatment upregulated
PMAIP1 expression in both cell lines, whereas viscum or viscumTT did not affect expression
compared to the control (Fig 4B). ViscumTT and viscum, but not TT, effectively downregu-
lated the anti-apoptotic protein, MCL1, in both cell lines compared to untreated control cells
(Fig 4B). These data suggest that TT upregulates pro-apoptotic PMAIP1 but is incapable of
downregulating MCL1, possibly explaining the less effective apoptotic induction of TT extract
alone. Taken together, our results indicate that cytotoxic agents derived from mistletoe invoke
several signaling pathways to induce apoptosis, which explains the synergistic effect of recon-
stituting a complete mistletoe extract in viscumTT.
calculated by Webb´s fractional product (*Fp > 1). Carbonyl cyanide m-chlorophenyl hydrazine (CCCP) was used as positive control. Mistletoe lectin
(ML) and oleanolic acid (OA) concentrations were used as a measure of viscum and TT active agent extract concentration, respectively.
doi:10.1371/journal.pone.0159749.g002
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ViscumTT and viscum induce apoptosis and inhibit proliferation ex vivo
and reduce xenograft tumor growth
We proceeded to verify our in vitro results in primary Ewing sarcoma cells grown ex vivo and
in human Ewing sarcoma xenograft tumors grown in nude mice. Ex vivo cultures of primary
Ewing sarcoma cells were treated with increasing concentrations of viscum, TT and viscumTT
for 24h. TT alone had no effect on primary Ewing sarcoma cells ex vivo (Fig 5 and S1 Table),
similarly to MHH-ES-1 cells. Treatment with viscum or viscumTT induced apoptosis in a con-
centration-dependent manner in primary Ewing sarcoma cells ex vivo, leading to mitochon-
drial membrane depolarization and CASP8 and CASP9 activation (Fig 5 and S1 Table).
Importantly, we also validated the synergistic effect of viscumTT in primary Ewing sarcoma
cells ex vivo (Fig 5 and S1 Table). We next tested the effect of viscum, TT and viscumTT on the
established human Ewing sarcoma cell line TC-71 grown subcutaneously in female NOD/
SCID IL2rγ null mice. Extracts were injected intratumorally every 2–3 days in increasing
Fig 3. ViscumTT synergistically activates caspases in Ewing sarcoma cells lines above the levels activated by viscum
alone. A. TC-71 and MHH-ES-1 cells treated 24h with either viscum, TT or viscumTT. CASP9, CASP8, CASP3 activation was
measured using FITC-LEHD-FMK, FITC-IETD-FMK and FITC-DEVD-FMK staining followed by flow cytometry. Bars represent
mean activation (±SD, error bars) in treatment groups from 3 independent experiments relative to untreated control cultures. A
synergist effect of the combined viscumTT extracts was calculated byWebb´s fractional product (*Fp > 1). B. TC-71 cells were
treated with viscum, TT and viscumTT for 24h with or without 40μM Z-VAD-FMK (pan-caspase inhibitor), then apoptotic cells were
detected using annexin V/propidium iodide staining and flow cytometry. Bars represent the mean (±SD, error bars) of 3
independent experiments. Results are expressed as percentages of the untreated control cultures. Mistletoe lectin (ML) and
oleanolic acid (OA) concentrations were used as a measure of viscum and TT active agent extract concentration, respectively.
doi:10.1371/journal.pone.0159749.g003
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concentrations with each concentration being administered twice and a total of five treatments
of TT, viscum or viscumTT (Fig 6). ViscumTT was also intravenously applied six times in one
treatment group to assess systemic effects on tumor growth (Fig 6). We included a positive
control group that received a single intravenous dose of the classical cytostatic agent, doxorubi-
cin (Fig 6). The negative control group received the solubilizing agents, cyclodextrins, injected
either intratumorally or intravenously (Fig 6). The administered extract concentrations were
well-tolerated by mice, which displayed no significant weight loss or toxicity symptoms. All
intratumorally injected Viscum album L. extracts significantly inhibited tumor growth by 50–
70% (as assessed from final measurement of mean tumor volumes compared to controls intra-
tumorally injected with cyclodextrins alone), with viscum most strongly inhibiting tumor
growth (Fig 6). Intravenously administered viscumTT inhibited tumor growth by 65% (com-
pared to controls receiving the cyclodextrin adjuvant intravenously, and achieved a comparable
effect to doxorubicin, which reduced tumor growth by 62% (Fig 6). In addition, a patient
Fig 4. Viscum, TT and viscumTT alter apoptosis-related protein expression. A.Whole-cell protein extracts from TC-71 cells after 24h of treatment
with viscum, TT or viscumTT concentrations approximating the IC50 were analyzed using the R&D systems human proteome profiler apoptosis array
(n = 1). Bars represent the n-fold change in apoptosis-related protein expression relative to untreated control expression.B. TC-71 and MHH-ES-1 cells
were treated with viscum, TT or viscumTT at the concentrations shown for 24h, then expression of the apoptosis-related proteins indicated was examined
in whole-cell lysates using western blotting. Representative pictures are shown from 3 independent experiments. Mistletoe lectin (ML) and oleanolic acid
(OA) concentrations were used as a measure of viscum and TT active agent extract concentration, respectively.
doi:10.1371/journal.pone.0159749.g004
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derived xenograft was treated with viscumTT that was injected intratumorally (low and high
dose) or intravenously (low dose) every 2–3 days in increasing concentrations and a total of
nine treatments. We included a positive control group that received twice an intravenous dose
of doxorubicin (Fig 7). The negative control group received cyclodextrins intratumorally (Fig
7). Again, the administered extract concentrations were well-tolerated by mice, which dis-
played no significant weight loss or toxicity symptoms. The intratumorally injected low and
high dose of viscumTT significantly inhibited tumor growth by 66–71% (as assessed from final
measurement of mean tumor volumes compared to controls intratumorally injected with
cyclodextrins alone). By contrast, intravenously administered viscumTT and doxorubicin did
not inhibit tumor growth significantly. Taken together, reconstituting whole mistletoe extract
in viscumTT synergistically induced apoptosis in primary Ewing sarcoma cells ex vivo and
effectively suppressed Ewing sarcoma growth in xenograft mouse models.
Discussion
The combined mistletoe extract, viscumTT, inhibits proliferation and induces apoptosis in
Ewing sarcoma cells in vitro and ex vivo, and efficiently reduces xenograft tumor volume in
vivo. While viscum alone showed similar but less effective anticancer activity in vitro and ex
vivo, the triterpene extract, TT, displayed significant activity only against TC-71 cells in vitro
and TC-71 xenografts in vivo. Although it is ineffective against MHH-ES-1 and primary Ewing
Fig 5. ViscumTT and viscum induce apoptosis and inhibit proliferation ex vivo. Primary Ewing sarcoma cells from a 15-year-old girl were grown as
short-term cultures ex vivo, and treated with increasing concentrations of viscum, TT or viscumTT for 24h. Induction of apoptosis (n = 4), proliferation
inhibition (n = 2), mitochondrial membrane potential (n = 2) and activation of CASP8 and CASP9 (n = 2) were measured flow cytometrically with the same
assays described for the cell lines. Values are the means of n experiments ±SD (error bars). Controls were untreated cultures grown in parallel. A
synergistic effect of the combined viscumTT extracts was calculated byWebb´s fractional product (*Fp > 1). Mistletoe lectin (ML) and oleanolic acid (OA)
concentrations were used as a measure of viscum and TT active agent extract concentration, respectively.
doi:10.1371/journal.pone.0159749.g005
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sarcoma cells, TT appears to potentiate the effect of viscum, creating the synergistic effect of
viscumTT. Our data correlates with the well-known phytopharmacological phenomenon that
a naturally existing combination is often more effective than the single compounds [38,39].
Our in vitro and ex vivo experiments showed viscumTT and viscum invoke both intrinsic
and extrinsic pathways of apoptosis in Ewing sarcoma cells. Treatment of TC-71 cells with a
pan-caspase inhibitor verified that apoptosis was caspase-dependent. This is in line with previ-
ous data from hepatocellular carcinoma and leukemia [30,40–42]. Notably, MHH-ES-1 cells
and the primary cells were more resistant to mistletoe extracts than TC-71 cells, and required
~15-fold higher viscum concentrations to reach IC50. This demonstrates a variable responsive-
ness of different cell populations to viscum and viscumTT. Variable susceptibility could stem
from different cell surface characteristics (glycocalyx), since mistletoe lectins specifically bind
to D-galactose and/or N-acetyl-D-galactosamine [15] and therefore response to mistletoe lec-
tins is cell-type-dependent [43]. TT proved less cytotoxic than either viscumTT or viscum
against Ewing sarcoma cells. TT also did not activate CASP8, CASP9 or CASP3 or cause mito-
chondrial membrane depolarization, indicating other mechanisms cause the moderate TT-
mediated apoptosis and proliferative inhibition in TC-71 cells. Triterpene acids, such as ursolic
acid and oleanolic acid and its derivatives, have previously been shown to induce apoptosis in
osteosarcoma, breast and pancreatic cancers via extrinsic or intrinsic pathways requiring cas-
pases [25,44–48]. Oleanolic acid and its derivative have also been shown to induce apoptosis
without caspase participation in pancreatic cancer cells and acute myelogenous leukemia
[49,50], suggesting that the triterpene effect is cell type-dependent.
Our deeper assessment of the apoptotic mechanism after mistletoe extract treatment in
vitro revealed altered expression of diverse apoptosis-related proteins shifting the balance
towards apoptosis. Treatment with viscumTT and viscum effectively reduced expression of the
anti-apoptotic protein, MCL1. The MCL1 downregulation in Ewing sarcoma cell lines agrees
with previous data demonstrating MCL1 downregulation by mistletoe lectins in leukemia cells
[51] and by an oleanolic acid derivative in osteosarcoma cells [52]. TT strongly upregulated the
PMAIP1 pro-apoptotic protein in both Ewing sarcoma cell lines, but didn't affect MCL1
Fig 6. ViscumTT reduces the growth of human Ewing sarcoma xenograft tumors in mice. Established Ewing sarcoma xenograft tumors were
intratumorally (i.t.) injected with 40/50/60mg oleanolic acid/kg mouse weight (TT i.t.), 0.75/1.25/1.75μg mistletoe lectin /kg mouse weight (viscum i.t.) or a
combination thereof (viscumTT i.t.) every 2 to 3 days in increasing concentrations. Each concentration was administered twice within 2–3 days. One
treatment group received viscumTT intravenously (i.v.), and one positive control group was once intravenously (i.v.) treated with 4 mg/kg doxorubicin.
The negative control group received the solubilizing agent, cyclodextrins (CD), which was injected either intratumorally (CD i.t.) or intravenously (CD i.v.).
One-way ANOVA revealed a significant group effect (p = 0.007) and Fisher´s Least Significant Difference test comparing all groups with all groups
showed a significant effect between the CD i.t. control group and viscumTT i.t. (p = 0.033), viscum i.t. (p = 0.002) and TT i.t. (p = 0.021) as well as
between the CD i.v. control group and viscumTT i.v. (p = 0.014) or the positive control group, doxorubicin i.v. (p = 0.015). Box-and-wisker plots each
represent one treatment group including 8 mice (*p < 0.05, **p < 0.005).
doi:10.1371/journal.pone.0159749.g006
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expression resulting in less effective apoptosis induction. PMAIP1 upregulation together with
downregulation of the anti-apoptotic BCL2L1 protein have been correlated with increased apo-
ptosis in pancreatic tumor cells treated with an oleanolic acid derivative [53]. Erhardt et al.
reported that PMAIP1 is involved in apoptotic induction by drug combinations, such as doxo-
rubicin and betulinic acid in diverse cancer cell lines, including breast, colon and leukemia
[37]. ViscumTT contains oleanolic and betulinic acid, viscotoxins, mistletoe lectins and other
undefined components, which together produce a phytopolychemotherapeutic effect. But
unlike TT, viscumTT did not upregulate PMAIP1 expression in Ewing sarcoma cells, indicat-
ing PMAIP1 regulation is not involved in the synergistic effect produced by viscumTT. Mistle-
toe extracts also suppressed TP53 expression in Ewing sarcoma cell lines, but this effect is less
Fig 7. ViscumTT reduces the growth of patient-derived Ewing sarcoma xenograft tumors in mice. Established Ewing sarcoma xenograft tumors
in NMRI-nu/nu mice were intratumorally (i.t.) and intravenously (i.v.) injected with 40/60/80mg/kg oleanolic acid and 1.25/1.75/2.25μg/kg mistletoe
lectin in combination (viscumTT, low dose). Additionally, mice were treated intratumorally (i.t.) with 50/70/90mg/kg oleanolic acid and 1.25/1.75/
2.25μg/kg mistletoe lectin in combination (viscumTT, high dose). Viscum TT was given every 2–3 days in increasing extract concentrations. One
positive control group was treated twice intravenously (i.v.) with 4 mg/kg doxorubicin. The negative control group received cyclodextrins (CD)
intratumorally (CD i.t.). One-way ANOVA revealed a strongly significant group effect (p < 0.0001) and Fisher´s Least Significant Difference test
comparing all groups with all groups showed a significant effect between the CD i.t. control group and viscumTT i.t. low dose (p = 0.006) and viscumTT
i.t. high dose (p = 0.003) Box-and-wisker plots each represent one treatment group including 5 mice (**p < 0.005).
doi:10.1371/journal.pone.0159749.g007
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meaningful since TC-71 expresses an inactive TP53 mutant protein [54] and MHH-ES-1 har-
bors an in-frame deletion of Ser215 in the TP53 transactivation domain. The downregulation
might indicate signaling is in place that would trigger downregulation of the wild type tumor
suppressor. However, this must not mean it would have an anti-apoptotic effect, since mistletoe
lectins both suppressed wild type TP53 expression and induced apoptosis in human lympho-
cytes [55]. Other reports did not analyze TP53 expression directly, but also showed that Viscum
album L. induced apoptosis in cell lines (SMMC7721 hepatocellular carcinoma and NALM-6
acute lymphoblastic leukemia cells) harboring wild type TP53 [30,42]. CLSPN expression was
also decreased in both cell lines after treatment with viscumTT or either single extract. It is
required for efficient DNA replication during a normal S phase and has been shown to pro-
mote cancer cell survival [56]. CLSPN is an essential upstream regulator of checkpoint kinase
1, and triggers cell cycle arrest in response to replicative stress or DNA damage. In a previous
study, we showed that mistletoe extracts similarly reduced CLSPN expression in acute myeloid
leukemia cells, where extracts also induced apoptosis and inhibited proliferation [31]. Mistletoe
extracts also reduced XIAP and BIRC5 expression in Ewing sarcoma cells. The IAP family reg-
ulates cell death by inhibiting caspases or the assembly of pro-apoptotic protein complexes,
and mediating the expression of anti-apoptotic proteins [57,58]. Since BIRC5 expression is
associated with chemo- and radioresistance in Ewing sarcoma and poor patient prognosis
[9,10], BIRC5 downregulation by Viscum album L. extracts makes it an interesting candidate
for targeting Ewing sarcoma. We previously achieved a similar effect with acute myeloid leuke-
mia cells [31]. Oleanolic and ursolic acid have also been shown to induce apoptosis and down-
regulate XIAP in hepatocellular carcinoma cells [47], while oleanolic acid decreased BIRC5
expression in human nonsmall cell lung cancer and ovarian cancer cells [27,59] and betulinic
acid derivatives downregulated BIRC5 in glioblastoma cell lines [60]. Taken together, our in
vitro data shows that viscumTT combines the anti-cancer effects derived from triterpene acids
and mistletoe lectins, and pro-apoptotically shifts the balance of apoptosis-related proteins,
suggesting this effect is not cancer-type dependent.
The anticancer effects we observed for mistletoe extract ex vivo and in vitro, were confirmed
in vivo in a TC-71 cell line and patient-derived xenograft model for Ewing sarcoma. In the TC-
71 xenograft, all extracts inhibited the tumor growth significantly when injected intratumo-
rally. Intravenous injection of viscumTT had a comparable effect on the tumor growth to doxo-
rubicin treatment. However, doxorubicin was applied only once due to bad tolerability in mice.
Still, this also emphasizes the good tolerability of the used mistletoe extracts. Noteworthy, we
were not able to observe a synergistic effect of viscumTT in vivo. However, identical results in
vitro and in vivo are impossible, since a living organism is more than one cell type and the
extracts are metabolized in the body. Unfortunately, there is literature lacking showing the
pharmacokinetics of mistletoe extracts in mice or humans, but Huber et al. showed for subcu-
taneous injections in humans, that serum mistletoe lectin levels are highly variable after injec-
tion [61]. Furthermore, Frantz et al. demonstrated, that mistletoe lectins can also bind Serum
glycoproteins as haptoglobin, alpha 1-acid glycoprotein and transferrin inhibiting the cytotox-
icity of the lectins [62] Although viscumTT had no synergistic effect in vivo, it still demon-
strated effectiveness intratumorally and intravenously. To validate the effect of viscumTT in
vivo, we injected viscumTT in a patient-derived xenograft model intratumorally and intrave-
nously. The intratumorally injected viscumTT in low and high dose significantly reduced
tumor growth, while twice application of doxorubicin showed no significant tumor reduction.
Notably, viscumTT intratumoral displayed different results depending on the used mouse stem
demonstrating the difficulties to evaluate in vitro results in vivo. Mistletoe lectins have also
been reported to have an anticancer effect in mouse models for melanoma, pre-B ALL and lym-
phosarcoma [63–65], as were oleanolic acid and its derivatives in mouse models of melanoma,
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osteosarcoma and lung cancer [27,66,67]. We and others have previously demonstrated the in
vivo efficacy of viscumTT against mouse models of acute lymphoblastic leukemia and mela-
noma [30,33].
Here we demonstrate that reconstituting the aqueous and triterpene components from mis-
tletoe in the viscumTT extract synergistically induces caspase-dependent apoptosis associated
with CLSPN, MCL1, BIRC5 and XIAP downregulation in Ewing sarcoma cell lines in vitro and
primary cells ex vivo. ViscumTT also reduced tumor growth in TC-71- derived and patient-
derived Ewing sarcoma xenografts. ViscumTT may represent a phytopolychemotherapeutic
option as a promising adjuvant therapy for patients with Ewing sarcoma.
Supporting Information
S1 Table. All in vitro and ex vivomeasurements. TC-71 cells, MHH-ES-1 cells and Ewing sar-
coma primary cells were incubated for 24 h with the extracts in depicted concentrations fol-
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